Kura Oncology, Inc. 2025 Q4 - Results - Earnings Call Presentation
…
9,390$
4,86%
Echtzeit-Aktienkurs Kura Oncology
Bid:
Ask:
Nachrichten zur Kura Oncology Aktie
Kura Oncology to Report Fourth Quarter and Full Year 2025 Financial Results
SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to…
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company…
Kura Oncology: H.C. Wainwright bestätigt Kaufempfehlung - Aufnahme von Komfiziti in National Comprehensive Cancer Network Guidelines wird gelobt
Kura Oncology Inc. (KURA) ist ein Biotechnologieunternehmen, welches sich sich auf die Entwicklung präzisionsmedizinischer Therapien zur Krebsbehandlung konzentriert. Der Fokus…
Kura Oncology stock rises after promising cancer drug combination data By Investing.com
Kura Oncology stock rises after promising cancer drug combination data…
Kura Oncology, Inc. (KURA) Discusses Clinical Updates on Farnesyl Transferase Inhibitor Programs and Combination Therapies in Oncology Transcript
…
Kura Oncology at ESMO Congress 2025: Promising Cancer Therapies By Investing.com
Kura Oncology at ESMO Congress 2025: Promising Cancer Therapies…
Kura Oncology, Inc. (KURA) Presents at UBS Virtual Oncology Day Transcript
…
Kura Oncology and Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition of NPM1 and FLT3 Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
– Expanding clinical experience and safety profile of ziftomenib support its evaluation in combination with approved FLT3 inhibitors in frontline AML…
Kura Oncology (KURA) Reports Q2 Loss, Lags Revenue Estimates
Kura Oncology (KURA) delivered earnings and revenue surprises of -600.00% and -89.23%, respectively, for the quarter ended June 2025. Do…
Kura Oncology to Report Second Quarter 2025 Financial Results
SAN DIEGO, July 31, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed…
KURA Stock Rises More Than 15% This Past Week: Heres Why
Kura Oncology shares rise this week after the FDA accepts its NDA for ziftomenib, a potential first-in-class treatment for NPM1-mutant…
Kura Oncology, Inc. 2024 Q4 - Results - Earnings Call Presentation
…
Kura Oncology (KURA) Reports Q4 Loss, Lags Revenue Estimates
Kura Oncology (KURA) delivered earnings and revenue surprises of 65.08% and 76.49%, respectively, for the quarter ended December 2024. Do…
Kura Oncology Inc. (KURA): H.C. Wainwright sieht 379 % Kurspotenzial und verweist auf die Studienfortschritte!
Kura Oncology Inc. (KURA) ist ein Biotech, welcher sich auf die Entwicklung von Präzisionsmedikamenten zur Behandlung von Krebs spezialisiert hat.…
Kura Oncology tumbles as Kyowa collaboration seen hitting M&A prospects By Investing.com
Kura Oncology tumbles as Kyowa collaboration seen hitting M&A prospects…
Kura Oncology, Inc. (KURA) Q3 2024 Earnings Call Transcript
…
Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting
– Ziftomenib combined with 7+3 in 1L NPM1-m or KMT2A-r adverse risk AML patients selected for oral presentation on Saturday,…
Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology
SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed…
Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of Directors
SAN DIEGO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed…
Kura Oncology, Inc. (KURA) Q2 2024 Earnings Call Transcript
…
Kura Oncology to Participate in Jefferies Global Healthcare Conference
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed…
Kura Oncology executive sells over $57k in company stock By Investing.com
Kura Oncology executive sells over $57k in company stock…
Kura Oncology to Participate in Bank of America Securities Healthcare Conference
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed…
Kura Oncology, Inc. (KURA) Q1 2024 Earnings Call Transcript
…
Kura Oncology to Report First Quarter 2024 Financial Results
SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed…
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, April 05, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical…
Earnings call: Kura Oncology reports promising trial results, financial outlook By Investing.com
Earnings call: Kura Oncology reports promising trial results, financial outlook…
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, March 01, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical…
Kura Oncology, Inc. (KURA) Q4 2023 Earnings Call Transcript
…